Summary of the baseline clinical, imaging and demographic characteristics of the study population (n=214)*
| Characteristics | Value |
|---|---|
| Male (n (%)) | 168 (78.5) |
| Age (years) | 40 (32, 46) |
| Disease duration (years) | 9 (3, 16) |
| BMI (kg/m2) | 25.5 (22.6, 27.9) |
| History of uveitis (n (%)) | 135 (63.1) |
| History of psoriasis (n (%)) | 20 (9.3) |
| History of IBD (n (%)) | 15 (7.0) |
| HLA-B27 positive (n (%))† | 191 (89.7) |
| BASMI | 4.6 (3.6, 5.8) |
| ASDAS | 4.0 (3.4, 4.6) |
| BASDAI | 6.5 (5.3, 7.0) |
| CRP level (mg/dl)‡ | 1.5 (0.7, 2.9) |
| mSASSS | 13.8 (4.5, 29.1) |
| ASspiMRI-a | 4.5 (0.5, 9.8) |
↵* Except were indicated otherwise, values are the median (IQR);
↵† one patient was not assessed for HLA-B27 status;
↵‡ normal range 0–0.5 mg/dl.
ASDAS, Ankylosing Spondylitis Disease Activity Score; ASspiMRI-a, Ankylosing Spondylitis spinal MRI activity; BASDAI, Bath Anklyosing Spondylitis Disease Activity Index; BASMI, linear definition of the Bath Ankylosing Spondylitis Metrology Index; BMI, body mass index; CRP, C-reactive protein; IBD, inflammatory bowel disease; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score.